Oncology Drug Reference Sheet: Avapritinib
Kristine B. LeFebvre MSN, RN, AOCN®
Voice
Description
First approved by the U.S. Food and Drug Administration in 2020 for treatment of gastrointestinal stromal tumors (GIST), avapritinib’s (AyvakitTM) approval was extended in 2021 for treatment of advanced systemic mastocytosis (AdvSM). Both approvals are for patients with PDGFR-alpha genetic variants.
ONS Drug Education
Short summaries of newly approved oncology-related therapies or drugs with new indications.
View All Drug Education